Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Hardwick RN"'
Publikováno v:
Clinical Pharmacology & Therapeutics; Apr2017, Vol. 101 Issue 4, p453-457, 5p
Autor:
Stresser DM; Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA. david.stresser@abbvie.com.; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), . david.stresser@abbvie.com.; IQ Microphysiological Systems Affiliate (IQ-), . david.stresser@abbvie.com., Kopec AK; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., Hewitt P; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Chemical and Preclinical Safety, Merck KGaA, Darmstadt, Germany., Hardwick RN; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Toxicology, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, San Diego, CA, USA., Van Vleet TR; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology and Pathology, AbbVie, North Chicago, IL, USA., Mahalingaiah PKS; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology and Pathology, AbbVie, North Chicago, IL, USA., O'Connell D; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; Global Animal Welfare, AbbVie, North Chicago, IL, USA.; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group., Jenkins GJ; Quantitative, Translational & ADME Sciences, AbbVie, North Chicago, IL, USA.; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Translational and ADME Sciences Leadership Group (TALG)., David R; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK., Graham J; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; Product Quality & Occupational Toxicology, Genentech, Inc., South San Francisco, CA, USA.; IQ DruSafe.; Safety Assessment, Genentech, Inc., South San Francisco, CA, USA., Lee D; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Safety Assessment, Genentech, Inc., South San Francisco, CA, USA., Ekert J; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; UCB Pharma, Cambridge, MA, USA., Fullerton A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology, Genentech, Inc., South San Francisco, CA, USA., Villenave R; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Bajaj P; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Global Investigative Toxicology, Preclinical Safety, Sanofi, Cambridge, MA, USA., Gosset JR; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Pfizer, Inc, Cambridge, MA, USA., Ralston SL; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Preclinical Safety, AbbVie, North Chicago, IL, USA., Guha M; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Biology, Incyte, Wilmington, DE, USA., Amador-Arjona A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Discovery Biology, Incyte, Wilmington, DE, USA., Khan K; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, UK., Agarwal S; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Investigative Toxicology, Early Development, Alnylam Pharmaceuticals, Cambridge, MA, USA., Hasselgren C; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ DruSafe.; Predictive Toxicology, Genentech, Inc., South San Francisco, CA, USA., Wang X; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Translational Safety & Bioanalytical Sciences, Amgen Research, Amgen Inc., South San Francisco, CA, USA., Adams K; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ 3Rs (Replacement, Reduction, Refinement) Translational and Predictive Sciences Leadership Group.; Laboratory Animal Resources, Incyte, Wilmington, DE, USA., Kaushik G; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA., Raczynski A; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ).; IQ Microphysiological Systems Affiliate (IQ-).; Preclinical Safety Assessment, Vertex Pharmaceuticals, Inc, Boston, MA, USA., Homan KA; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), . homan.kimberly@gene.com.; IQ Microphysiological Systems Affiliate (IQ-), . homan.kimberly@gene.com.; Complex in vitro Systems Group, Genentech, Inc., South San Francisco, CA, USA. homan.kimberly@gene.com.
Publikováno v:
Nature biomedical engineering [Nat Biomed Eng] 2024 Aug; Vol. 8 (8), pp. 930-935.
Autor:
Tomlinson L; Global Pathology, Pfizer Inc., Cambridge, MA, 02140, USA., Ramsden D; DMPK Oncology, AstraZeneca, Boston, MA, 02451, USA., Leite SB; European Commission Joint Research Centre, Ispra, 21027, Italy., Beken S; Federal Agency for Medicines and Health Products, Brussels, 1210, Belgium., Bonzo JA; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Brown P; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Candarlioglu PL; Complex In Vitro Models, GSK, Stevenage, SG1 2NY, UK., Chan TS; Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 06877, USA., Chen E; DMPK, Genentech, South San Francisco, CA, 94080, USA., Choi CK; Preclinical Safety, Biogen, Cambridge, MA, 02142, USA., David R; Clinical Pharmacology & Safety Sciences, AstraZeneca, Cambridge, CB2 0AA, UK., Delrue N; Organisation for Economic Co-operation and Development, Paris, 75016, France., Devine PJ; Discovery Toxicology, Bristol Myers Squibb, San Diego, CA, 09130, USA., Ford K; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Garcia MI; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Gosset JR; DMPK, Pfizer Inc., Cambridge, MA, 02139, USA., Hewitt P; Chemical and Preclinical Safety, Merck Healthcare KGaA, 64293, Darmstadt, Germany., Homan K; Complex in Vitro Systems Group, Genentech, South San Francisco, CA, 94080, USA., Irrechukwu O; Preclinical Sciences and Translational Safety, Johnson and Johnson Innovation Medicine, Spring House, PA, 19002, USA., Kopec AK; Drug Safety Research & Development, Pfizer Inc., Groton, CT, 06340, USA., Liras JL; Pharmacokinetics, Dynamics & Metabolism-Medicine Design, Pfizer, Cambridge, MA, 02139, USA., Mandlekar S; Clinical Pharmacology, Genentech, South San Francisco, CA, 94080, USA., Raczynski A; Preclinical Safety Assessment, Vertex Pharmaceuticals Inc., Boston, MA, 02210, USA., Sadrieh N; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sakatis MZ; Non-Clinical Safety, In Vitro/In Vivo Translation, GSK R&D, Ware, SG12 9TJ, UK., Siegel J; Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sung K; Center for Biologics Evaluation and Research, Office of Cellular Therapy and Human Tissue, Cellular and Tissue Therapy Branch, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA., Sunyovszki I; Translational Cellular Sciences, Biogen, Cambridge, MA, 02142, USA., Van Vleet TR; AbbVie, Inc., North Chicago, IL, 60064, USA., Ekert JE; UCB Pharma, Cambridge, MA, 02140, USA., Hardwick RN; Discovery Toxicology, Bristol Myers Squibb, San Diego, CA, 09130, USA.
Publikováno v:
Advanced biology [Adv Biol (Weinh)] 2024 Aug; Vol. 8 (8), pp. e2300131. Date of Electronic Publication: 2023 Oct 09.
Autor:
Lim AY; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA., Kato Y; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.; Laboratory for Drug Discovery and Development, Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Osaka 561-0825, Japan., Sakolish C; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA., Valdiviezo A; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA., Han G; Department of Epidemiology and Biostatistics, Texas A&M University, College Station, TX 77843, USA., Bajaj P; Global Investigative Toxicology, Preclinical Safety, Sanofi, Cambridge, MA 02141, USA., Stanko J; Division of Translational Toxicology, National Institute of Environmental Health Sciences, Durham, NC 27709, USA., Ferguson SS; Division of Translational Toxicology, National Institute of Environmental Health Sciences, Durham, NC 27709, USA., Villenave R; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland., Hewitt P; Chemical and Preclinical Safety, Merck Healthcare KGaA, 64293 Darmstadt, Germany., Hardwick RN; Discovery Toxicology, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, San Diego, CA 92121, USA., Rusyn I; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.
Publikováno v:
Bioengineering (Basel, Switzerland) [Bioengineering (Basel)] 2023 Oct 14; Vol. 10 (10). Date of Electronic Publication: 2023 Oct 14.
Autor:
Wang X; Translational Safety & Bioanalytical Sciences, Amgen Research, Amgen, Inc., South San Francisco, CA, USA., Kopec AK; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., Collinge M; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., David R; Safety Innovation, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Grant C; Preclinical Safety, AbbVie, Inc., Worcester, MA, USA., Hardwick RN; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, CA, USA.; current affiliation: Discovery Toxicology, Preclinical Candidate Optimization, Bristol Myers Squibb, San Diego, CA, USA., Navratil A; Biology and Pharmacology, Theravance Biopharma US, Inc., South San Francisco, CA, USA., Patel N; Preclinical Safety, Research and Development, Sanofi-Aventis US, LLC, Framingham, MA, USA., Rowan W; Novel Human Genetics, GSK, Stevenage, UK., Marshall N; Non-Clinical Safety, GSK, Collegeville, PA, USA.
Publikováno v:
ALTEX [ALTEX] 2022 Aug 29; Vol. 40 (2), pp. 314–336. Date of Electronic Publication: 2022 Aug 29.
Autor:
Rusyn I; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas 77843, USA., Sakolish C; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas 77843, USA., Kato Y; Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas 77843, USA., Stephan C; Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA., Vergara L; Institute of Biosciences and Technology, Texas A&M University, Houston, Texas 77030, USA., Hewitt P; Chemical and Preclinical Safety, Merck Healthcare KGaA, Darmstadt, Germany., Bhaskaran V; Discovery Toxicology, Bristol Myers Squibb, Princeton, New Jersey 08543, USA., Davis M; Discovery Toxicology, Bristol Myers Squibb, Princeton, New Jersey 08543, USA., Hardwick RN; Discovery Toxicology, Bristol Myers Squibb, San Diego, California 92130, USA., Ferguson SS; Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA., Stanko JP; Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA., Bajaj P; Global Investigative Toxicology, Preclinical Safety, Sanofi, Framingham, Massachusetts 01701, USA., Adkins K; Global Investigative Toxicology, Preclinical Safety, Sanofi, Framingham, Massachusetts 01701, USA., Sipes NS; Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, 27711, USA., Hunter ES; Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, 27711, USA., Baltazar MT; Unilever Safety and Environmental Assurance Centre, Bedfordshire, Sharnbrook MK44 1LQ, UK., Carmichael PL; Unilever Safety and Environmental Assurance Centre, Bedfordshire, Sharnbrook MK44 1LQ, UK., Sadh K; Unilever Safety and Environmental Assurance Centre, Bedfordshire, Sharnbrook MK44 1LQ, UK., Becker RA; American Chemistry Council, Washington, District of Columbia 20002, USA.
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2022 Jul 28; Vol. 188 (2), pp. 143-152.
Autor:
Hardwick RN; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA., Brassil P; Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA., Badagnani I; Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA., Perkins K; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA., Obedencio GP; Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA., Kim AS; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA., Conner MW; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA., Bourdet DL; Drug Metabolism and Pharmacokinetics, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA., Harstad EB; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, California 94080, USA.
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2022 Mar 28; Vol. 186 (2), pp. 323-337.
Autor:
Baran SW; Emerging Technologies, Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Brown PC; U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Silver Spring, MD, USA., Baudy AR; ADME & Discovery Toxicology, Merck & Co., Inc., Kenilworth, NJ, USA., Fitzpatrick SC; U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of the Center Director, College Park, MD, USA., Frantz C; Translational Sciences, Seagen, Seattle, WA, USA., Fullerton A; Safety Assessment, Genentech, South San Francisco, CA, USA., Gan J; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, Princeton, NJ, USA., Hardwick RN; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, CA, USA., Hillgren KM; Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA., Kopec AK; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA., Liras JL; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Cambridge, MA, USA., Mendrick DL; U.S. Food and Drug Administration, National Center for Toxicological Research, Office of the Center Director, Silver Spring, MD, USA., Nagao R; Translational Sciences, Seagen, Seattle, WA, USA., Proctor WR; Safety Assessment, Genentech, South San Francisco, CA, USA., Ramsden D; Global Drug Metabolism and Pharmacokinetics, Takeda Pharmaceuticals International Co., Cambridge, MA, USA., Ribeiro AJS; U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Clinical Pharmacology, Division of Applied Regulatory Science, Silver Spring, MD, USA., Stresser D; Drug Metabolism, Pharmacokinetics and Bioanalysis, AbbVie, Inc., North Chicago, IL, USA., Sung KE; U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies, Division of Cellular and Gene Therapies, Silver Spring, MD, USA., Sura R; Global Preclinical Safety, AbbVie Inc., North Chicago, IL, USA., Tetsuka K; Analysis & Pharmacokinetics Research Labs., Astellas Pharma Inc., Tsukuba-shi, Ibaraki, Japan., Tomlinson L; Global Pathology, DSRD, Pfizer WRD, Cambridge, MA, USA., Van Vleet T; AbbVie, Inc., Chicago, IL, USA., Wagoner MP; Drug Safety Research & Evaluation, Takeda Pharmaceuticals International Co., Cambridge, MA, USA., Wang Q; Drug Safety Research & Evaluation, Takeda Pharmaceuticals International Co., Cambridge, MA, USA., Arslan SY; BioAnalysis, Applied Research Management & Biomedical Science (AMS), Astellas Pharma Inc., Northbrook, IL, USA., Yoder G; Aimmune (Nestlé Health Sciences), Brisbane, CA, USA., Ekert JE; In Vitro In Vivo Translation, Research, Pharmaceutical R&D, GlaxoSmithKline, Collegeville, PA, USA.
Publikováno v:
ALTEX [ALTEX] 2022; Vol. 39 (2), pp. 297–314. Date of Electronic Publication: 2022 Jan 21.
Autor:
Loskill P; Department of Biomedical Engineering, Faculty of Medicine, Eberhard Karls University Tübingen, Tübingen, Germany; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany; 3R-Center for In vitro Models and Alternatives to Animal Testing, Eberhard Karls University Tübingen, Tübingen, Germany. Electronic address: peter.loskill@uni-tuebingen.de., Hardwick RN; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, CA, USA., Roth A; Personalized Healthcare Safety Interface, Product Development Safety, Roche Innovation Centre Basel, Basel, Switzerland.
Publikováno v:
Stem cell reports [Stem Cell Reports] 2021 Sep 14; Vol. 16 (9), pp. 2033-2037.